Compare PHAR & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | SIBN |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.4M | 778.8M |
| IPO Year | 2020 | 2018 |
| Metric | PHAR | SIBN |
|---|---|---|
| Price | $9.95 | $18.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.35 | $25.00 |
| AVG Volume (30 Days) | 32.7K | ★ 481.6K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,301,000.00 |
| Revenue This Year | $1.92 | $15.53 |
| Revenue Next Year | $8.85 | $15.64 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | ★ 21.53 |
| 52 Week Low | $9.62 | $11.48 |
| 52 Week High | $21.34 | $21.89 |
| Indicator | PHAR | SIBN |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 54.10 |
| Support Level | $9.62 | $16.34 |
| Resistance Level | $11.60 | $19.35 |
| Average True Range (ATR) | 0.40 | 0.54 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 7.95 | 60.39 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.